CoMFA and docking studies on glycogen phosphorylase a inhibitors as antidiabetic agents

Journal of Chemical Information and Modeling

Volumn 45, Issue 1, 2005, Pages 136-145

  Prathipati, Philip ^a   Pandey, Gyanendra ^a   Saxena, Anil K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DERIVATIVES; DISEASE CONTROL; ENZYME INHIBITION; GLUCOSE; HYDROGEN BONDS; MOLECULAR STRUCTURE; PHARMACOKINETICS; PHYSICAL CHEMISTRY; X RAY CRYSTALLOGRAPHY;

ANTIDIABETIC AGENTS; CATALYTIC SITES; GLYCOGEN; PLASMA GLUCOSE LEVEL;

POLYSACCHARIDES;

ANTIDIABETIC AGENT; GLYCOGEN PHOSPHORYLASE;

ARTICLE; BINDING SITE; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; HUMAN; PROTEIN BINDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

BINDING SITES; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PHOSPHORYLASE A; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 13844311049     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci049762u     Document Type: Article

References (71)

1. Kenny, S. J.; Aubert, R. E.; Geiss, L. S. Diabetes in America, 2nd ed.; Harris, M., Ed.; NIH publication: 1995; pp 47-67.
2. Panzram, G. Mortality and survival in Type 2 (Noninsulin-Dependent) Diabetes mellitus. Diabetotogia 1987, 30, 123-31.
3. Nathan, D. M.; Long-term Complications of diabetes mellitus. New Engl. J. Med. 1993, 328, 1676-85.
4. DeFronzo, R. A.; Bonadonna, R. C.; Ferrannini, E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992, 15, 8-369.
5. Consoli, A. Role of liver in pathophysiology of NIDDM. Diabetes Care 1992, 15, 430-441.
6. Gerich, J. E. Role of liver and muscle in type II diabetes. Horn. Metab. Res. 1992, 26, 18-21.
7. Martin, J. L.; Veluraja, K.; Johnson, L. N.; Fleet, G. W. J.; Ramsden, N. G.; Bruce, I.; Oikonomakos, N.G.; Papageorgiou, A. C.; Leonidas, D. D.; Tsitoura, H. S. Glucose analogue inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes. Biochemistry 1991, 30, 10101-10116.
8. Watson, K. A.; Mitchell, E. P.; Johnson, L. N.; Son, J. C.; Bichard, C. J. F.; Orchard, M. G.; Fleet, G. W. J.; Oikonoraakos, N. G.; Leonidas, D. D.; Kontou, M.; Papageorgiou, A. C. Design of inhibitors of glycogen phosphorylase: a study of alpha- and beta-C-glucosides and 1-thio-beta-D-glucose compounds. Biochemistry 1994, 33, 5745-5758.
9. Watson, K. A.; Mitchell, E. P.; Johnson, L. N.; Cruciani, G.; Son, J. C.; Bichard, C. J. F.; Fleet, G. W. J.; Oikonomakos, N. G.; Kontou, M.; Zographos, S. E. Glucose Analogue Inhibitors of Glycogen Phosphorylase: From Crystallographic Analysis to Drug Prediction Using GRID Force-Field and GOLPE Variable Selection. Acta Crystallogr. Sect. 1995, D51, 458-472.
10. Bichard, C. J. F.; Mitchell, E. P.; Wormald, M. R.; Watson, K. A.; Johnson, L. N.; Zographos, S. E.; Koutra, D. D.; Oikonomakos, N. G.; Fleet, G. W. J. Potent inhibition of glycogen phosphorylase by a spirohydantoin of glucopyranose: first pyranose analogues of hydantocidin. Tetrahedron Lett. 1995, 36, 2145-2148.
11. Oikonomakos, N. G.; Kontou, M.; Zographos, S. E.; Watson, K. A.; Johnson, L. N.; Bichard, C. J. F.; Fleet, G. W. J.; Acharya, K. R. N-acetyl-{beta}-D- glucopyranosylamine: A potent T-state inhibitor of glycogen phosphorylase. A comparison with {alpha}-D-glucose. Protein Sci. 1995, 4, 2469-2477.
12. Zographos, S. E.; Oikonomakos, N. G.; Tsitsanou, K. E.; Leonidas, D. D.; Chrysina, E. D.; Skamnaki, V. T.; Bischoff, H.; Goldman, S.; Schram, M.; Watson, K. A.; Johnson, L. N. The structure of glycogen phosphorylase b with an alkyldihydropyridine-dicarboxylic acid compound, a novel and potent inhibitor. Structure 1997, 5, 1413-1425.
13. Gregoriou, M.; Noble, M. E. M.; Watson, K. A.; Garman, E. F.; Krulle, T. M.; Fuente, C.; Fleet, G. W. J.; Oikonomakos, N. G.; Johnson, L. N. The structure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1.8 A resolution and 100 K: The role of the water structure and its contribution to binding. Protein Sci. 1998, 7, 915-927.
14. Oikonomakos, N. G.; Tsitsanou, K. E.; Zographos, S. E.; Skamnaki, V. T.; Goldmann, S.; Bischoff, H. Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1- ethyl-2-methyl-pyridine-3,5,6-tricarboxylate. Protein Sci. 1999, 8, 1930-1945.
15. Oikonomakos, N. G.; Skamnaki, V. T.; Tsitsanou, K. E.; Gavalas, N. G.; Johnson, L. N. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure 2000, 8, 575-984.
16. Johnson, L. N.; Hajdu, J.; Acharya, K. R.; Stuart, D. I.; McLaughlin, P. J.; Oikonomakos, N. G.; Barford, D. Allosteric Enzymes; CRC Press: Boca Raton, FL, 1989; pp 81-127.
17. Johnson, L. N. Glycogen phosphorylase: control by phosphorylation and allosteric effectors. FASEB J. 1992, 6, 2274-2282.
18. Oikonomakos, N. G.; Acharya, K. R.; Johnson, L. N. Rabbit muscle glycogen phosphorylase b. The structural basis of activation and catalysis (review). Post-translational Modification of Proteins; CRC Press: Boca Raton, FL, 1992; pp 81-151.
19. Newgard, C. B.; Hwang, P. K.; Fletterick, R. J. The family of glycogen phosphorylase, structure and function. Crit. Rev. Biochem. Mol. Biol. 1989, 24, 69-99.
20. Board, M.; Johnson, L. N. Effects of N-Acetyl-b-D-glucopyranosylamine on glycogen metabolism by isolated hepatocytes. Diabetes Res. 1995, 28, 95-109.
21. Con, C. F.; Cori, G. T. Mechanism of formation of hexosemonophosphate in muscle and isolation of a new phosphate ester. Proc. Soc. Exp. Biol. Med. 1936, 34, 720-705.
22. Hers, H. Etudes enzymatiques sur fragments hepatiques; application a la classification des glycogenoses. Rev. Int. Hepatol 1959, 9, 35-36.
23. Gorin, F. A.; Mullinax, R. L.; Ignacio, P. C.; Neve, R. L.; Kurnit, D. M. McArdle's and Hers' disases: glycogen phosphorylase transcriptional expression in human tissues. J. Neurogenet. 1987, 4, 293-308.
24. van den Berghe, G. The role of the liver in metabolic homeostasis: implications for inborn errors of metabolism. J. Inherit. Metab. Dis. 1991, 14, 407-20.
25. Puhakainen, I.; Koivisto, V. A.; Yki-Jarvinen, H. No reduction in total hepatic glucose output by inhibition of gluconeogenesis with ethanol in NIDDM patients. Diabetes 1991, 40, 1319-27.
26. Hoover, D. J.; Lefkowitz-Snow, S.; Burgess-Henry, J. L.; Martin, W. H.; Armento, S. J.; Stock, I. A.; McPherson, R. K.; Genereux, P. E.; Gibbs, E. M.; Treadway, J. L. Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase. J. Med. Chem. 1998, 41, 2934-2938.
27. Pan, D.; Liu, J.; Senese, C.; Hopfinger, A. J.; Tseng, Y. Characterization of a ligand-receptor binding event using receptor-dependent four-dimensional quantitative structure-activity relationship analysis. J. Med. Chem. 2004, 47(12), 3075-88.
28. Pan, D.; Tseng, Y.; Hopfinger, A. J. Quantitative structure-based design: formalism and application of receptor-dependent RD-4D-QSAR analysis to a set of glucose analogue inhibitors of glycogen phosphorylase. J. Chem. Inf. Comput. Sci. 2003, 43(5), 1591-607.
29. Zamora, I.; Oprea, T.; Cruciani, G.; Pastor, M.; Ungell, A. L. Surface descriptors for protein-ligand affinity prediction. J. Med. Chem. 2003, 46(1), 25-33.
30. Gohlke, H. Klebe DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. J. Med. Chem. 2002, 45(19), 4153-70.
31. Marchand-Geneste, N.; Watson, K. A.; Alsberg, B. K.; King, R. D. New approach to pharmacophore mapping and QSAR analysis using inductive logic programming. Application to thermolysin inhibitors and glycogen phosphorylase B inhibitors. J. Med. Chem. 2002, 45(2), 399-409.
32. So, S. S.; Karplus, M. Evaluation of designed ligands by a multiple screening method: application to glycogen phosphorylase inhibitors constructed with a variety of approaches. J. Comput.-Aided Mol. Des. 2001, 75(7), 613-47.
33. Venkatarangan, P.; Hopfinger, A. J. Prediction of ligand-receptor binding thermodynamics by free energy force field three-dimensional quantitative structure-activity relationship analysis: applications to a set of glucose analogue inhibitors of glycogen phosphorylase. J. Med. Chem. 1999, 42(12), 2169-79.
34. So, S. S.; Karplus, M. A comparative study of ligand-receptor complex binding affinity prediction methods based on glycogen phosphorylase inhibitors. J. Comput.-Aided Mol. Des. 1999, 13(3), 243-58.
35. Pastor, M.; Cruciani, G.; Clementi, S. Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. J. Med. Chem. 1997, 40(10), 1455-64.
36. Cruciani, G.; Watson, K. A. Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. J. Med. Chem. 1994, 37(16), 2589-601.
37. Kashaw, S. K.; Rathi, L.; Mishra, P.; Saxena, A. K. Development of 3D-QSAR models in cyclic ureidobenzenesulfonamides: human 3-Adrenergic receptor agonist. Bioorg. Med. Chem. Lett. 2003, 13, 2481-2484.
38. Saxena, A. K.; Ram, S.; Saxena, M.; Singh, N.; Prathipati, P.; Jain, P. C.; Singh, H. K.; Anand, N. QSAR studies in substituted 1,2,3,4,6,7,12,12a-octa- hydropyrazino[2′,1′:6,1]pyrido[3,4-b]indoles-a potent class of neuroleptics. Bioorg. Med. Chem. 2003, 11, 2085-2090.
39. Gupta, M. K.; Mishra, P.; Prathipati, P.; Saxena, A. K. 2D-QSAR in hydroxamic acid derivatives as peptide deformylase inhibitors and antibacterial agents. Bioorg. Med. Chem. 2002, 10, 3713-3716.
40. Babu, M. K.; Shakya, N.; Prathipati, P.; Kaskhedikar, S. G.; Saxena, A. K. Development of 3D-QSAR models for 5-Lipoxygenase antagonists: chalcones. Bioorg. Med. Chem. 2002, 10, 4035-4041.
41. Desai, B.; Sureja, D.; Naliapara, Y.; Shah, A.; Saxena, A. K. Synthesis and QSAR Studies of 4-Substituted phenyl-2,6-dimethyl-3,5-bis-N-(substituted phenyl) carbamoyl-1-4-dihydropyridines as potential antitubercular agents. Bioorg. Med. Chem. 2001, 9, 1993-1998.
42. Saxena, A. K.; Pandey, S. K.; Seth, P.; Singh, M. P.; Dikshit, M.; Carpy. A. Synthesis and QSAR Studies in 2-(N-aryl-N-aroyl) amino-4,5-dihydrothiazole Derivatives as Potential Antithrombotic Agents. Bioorg. Med. Chem. 2001, 9, 2025-2034.
43. Saxena, A. K.; Pandey, S. K.; Tripathi, R. C.; Raghubir, R. Synthesis, molecular modeling and QSAR studies in chiral 2,3-disubstituted-1,2,3,4- tetrahydro-9H-pyrido(3,4-b)indoles as potential modulators of opioid antinociception. Bioorg. Med. Chem. 2001, 9, 1559-1570.
44. Pandya, T.; Pandey, S. K.; Tiwari, M.; Chaturvedi, S. C.; Saxena, A. K. 3-D QSAR studies of triazolinone based balanced AT1/AT2 receptor antagonists. Bioorg. Med. Chem. 2001, 9, 291-300.
45. Rathi, L.; Kashaw, S. K.; Dixit, A.; Pandey, G.; Saxena, A. K. Pharmacophore identification and 3D-QSAR studies in JV-(2-benzoyl phenyl)-L-tyrosines as PPARy agonists. Bioorg. Med. Chem. 2004, 12, 63-69.
46. Tame J. R. H. Scoring functions: A view from the bench. J. Comput.-Aided Mol. Des. 1999, 13, 99-108.
47. Donini O. A. T.; Kollman P. A. Calculation and prediction of binding free energies for the matrix metalloproteinases. J Med. Chem. 2000, 43, 4180-4188.
48. Cramer, R. D.; Patterson, D. E.; Bunce, J. D. J. Am. Chem. Soc. 1988, 110, 5959-5967.
49. 3D QSAR in Drug Design, Theory, Methods, and Applications; Kubyini, H., Ed.; ESCOM Science Publishers B.V.: Leiden, 1993.
50. Norinder, U. The Alignment problem in 3D-QSAR: A combined approach using Catalyst and a 3D-QSAR technique. QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications; Sanz, F., Giraldo, J., Manaut, F., Eds.; Prous Science Publishers: Barcelona, 1995; pp 433-438.
51. Hoffmann, R. D.; Langer, T. Use of the Catalyst program as a new alignment tool for 3D-QSAR. QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications; Sanz, F., Giraldo, J., Manaut, F., Eds.; Prous Science Publishers: Barcelona, 1995; pp 466-469.
52. Semus, S. F. CoMFA: A field of dreams? http://www.netsci.org/Science/ Compchem/feature11.html.
53. Langer, T.; Hoffmann, R. D. On the Use of Chemical Function-Based Alignments as Input for 3D-QSAR. J. Chem. Inf. Comput. Sci. 1998, 38, 325-330.
54. Bureau, R.; Daveu, C.; Baglin, I.; Sopkova-De Oliveira Santos, J.; Lancelot, J. C.; Rault, S. Association of Two 3D QSAR Analyses. Application to the Study of Partial Agonist Serotonin-3 Ligands, J. Chem. Inf. Comput. Sci. 2001, 41, 815-823.
55. Zhu, L. L.; Hou, T. J.; Chen, L. R.; Xu, X. J. 3D QSAR Analyses of Novel Tyrosine Kinase Inhibitors Based on Pharmacophore Alignment. J. Chem. Inf. Comput. Sci. 2001, 41, 1032-1040.
56. Klebe, G.; Abraham, U.; Mietzner, T. Molecular Similarity Indices in a Comparative Analysis (CoMSIA) of Drug Molecules to Correlate and Predict Their Biological Activity. J. Med. Chem. 1994, 37, 4130-4146.
57. Viswanadhan, V. N.; Ghose, A. K.; Revankar, G. R.; Robins, R. K. Atomic Physicochemical Parameters for Three-Dimensional Structure Directed Quantitative Structure-Activity Relationships. 4. Additional Parameters for Hydrophobic and Dispersive Interactions and Their Application for an Automated Superposition of Certain Naturally Occurring Nucleoside Antibiotics. J. Chem. Inf. Comput. Sci. 1989, 29, 163-172.
58. Joseph-McCarthy, D.; Thomas, B. E., IV; Belmarsh, M.; Moustakas, D.; Alvarez, J. C. Pharmacophore-Based Molecular Docking to Account for Ligand Flexibility. Proteins: Struct., Fund., Genet. 2003, 51, 172-188.
59. (a) Ludi manual; version 2.3; December 1993.
60. (b) Bohm, H. J. LUDI; rule-based automatic design of new substituents for enzyme inhibitor leads. J. Comput.-Aided Mol. Des. 1992, 6, 593-606.
61. Wang, R.; Lu, Y.; Wang, S. Comparative evaluation of 11 scoring functions for molecular docking. J. Med. Chem. 2003, 46, 2287-303.
62. Catalyst tutorial; version 4.5; August 1999.
63. Hirashim, A.; Morimoto, M.; Kuwano, E.; Taniguchi, E.; Eto, M. Three-dimensional common-feature hypotheses for octopamine agonist arylethanolamines. J. Mot. Graphics Modell. 2002, 21, 81-7.
64. Golbraikh, A.; Tropsha, A. Beware of q2. J. Mol Graphics Modell. 2002, 20, 269-276.
65. Wold, S.; Martens, H.; Wold, H. 1983. The Multivariate Calibration Problem in Chemistry solved by the PLS Method. Proc. Conf. Matrix Pencils, Lecture Notes in Mathematics 973; Ruhe, A., Kågström, B., Eds.; Springer-Verlag: Heidelberg, 1982; pp 286-293.
66. Wold, S. Cross validatory estimation of the number of components in factor and principal components models. Technometrics 1978, 20, p 397.
67. Saxena A. K.; Prathipati P. Comparison of MLR, PLS and GA-MLR in QSAR analysis. SAR QSAR Environ. Res. 2003, 14, 433-446.
68. Systat; version 7.0.
69. Sybyl getting started manual; version 6.8; October 2001.
70. Bohacek, R. S.; McMartin, C. Definition and Display of Steric, Hydrophobic, and Hydrogen-Bonding Properties of Ligand Binding Sites in Proteins Using Lee and Richards Accessible Surfaces: Validation of a High-Resolution Tool for Drug Design. J. Med. Chem. 1992, 35, 1671-1684.
71. Kroemer, R. T.; Hecht, P. Replacement of steric 6-12 potential-derived interaction energies by atom-based indicator variables in CoMFA leads to models of higher consistency. J. Comput.-Aided Mol. Des. 1995, 9, 205-212.